Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Immuno-Oncology Europe 2019

Anish Suri's Biography



Anish Suri, Senior vice President and Chief Scientific Officer, Cue Biopharma, Inc.

Anish Suri is an immunologist with more than 20 years of experience in basic and translational research focused on immuno-oncology, autoimmune disorders, transplantation rejection, and inflammation. Prior to joining Cue Biopharma, he held roles of increasing responsibility at Janssen Pharmaceutical Companies, most recently as Senior Director at Janssen Immunosciences. Prior to Janssen, he was responsible for providing strategic guidance to immuno-oncology and immunology drug discovery programs at Bristol-Myers Squibb Pharmaceutical Research Institute. Prior to his work in the pharmaceutical industry, Dr. Suri was Assistant Professor of Pathology and Immunology at Washington University School of Medicine. He received his Ph.D. in immunology from Washington University.

Anish Suri Image

Immuno-STATs™: A Novel Biologics Platform for Antigen-Specific Immunotherapy

Tuesday, 29 October 2019 at 11:30

Add to Calendar ▼2019-10-29 11:30:002019-10-29 12:30:00Europe/LondonImmuno-STATs™: A Novel Biologics Platform for Antigen-Specific ImmunotherapyImmuno-Oncology Europe 2019 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com

Immuno-STATs are proprietary biologics that incorporate, in a single molecular framework, key signals needed to selectively modulate antigen-specific T cells: namely, the pMHC-complex and relevant co-stimulatory/co-inhibitory signals, dependent upon the disease indication. The modularity and versatility of the platform allows for incorporation of diverse HLA alleles, different T cell epitopes along with various biologically relevant activating or regulatory signals. This ability to generate polyspecific therapeutic molecules enables targeting diverse geographical patient populations encompassing numerous disease indications. Harnessing selective immune-targeting while avoiding broad non-specific modulation of the immune system should provide a superior safety and therapeutic profile. Mechanistic data to this end will be discussed. The lead clinical candidate CUE-101 is comprised of HLA-A*0201, genetically bound to a HPV16 epitope (E7 protein, peptide 11-20), along with affinity-attenuated human interleukin-2 to selectively activate and expand HPV16 E711-20-specific CD8+ T cells for HPV-driven malignancies.


Add to Calendar ▼2019-10-28 00:00:002019-10-29 00:00:00Europe/LondonImmuno-Oncology Europe 2019Immuno-Oncology Europe 2019 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com